Pharmaceutical company Veeva Systems has announced that Sanofi is implementing its solutions to improve the latter’s quality management process.

The move includes the deployment of Veeva Vault QMS and Veeva Vault QualityDocs into Sanofi’s operations.

Sanofi’s consumer healthcare (CHC) division has already gone live with the implementation.

CHC division has also chosen Veeva Vault Training to consolidate its content management and GxP [good practice] training.

Sanofi plans to implement the Veeva solutions across the remainder of its units in 2023-2024.

Deployment of the unified Veeva Vault Quality Suite will help Sanofi to boost its wider digital transformation activities and to standardise quality management across its units and sites on an improved cloud platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sanofi chief quality officer Maïté Durrenbach stated: “Building a strong foundation of quality systems and processes is critical to our success.

“Veeva Vault Quality Suite delivers a highly scalable enterprise solution that supports our ambition to set up a more dynamic quality operating model, which is high-performing and data-driven.

“This will enable the Sanofi Play to Win transformation.”

The latest development comes shortly after Sanofi entered an exclusive worldwide licence agreement with Maze Therapeutics for Pompe disease therapy.

The deal includes Maze’s glycogen synthase 1 (GYS1) programme and oral substrate reduction therapy, MZE001.